Skip to Content

Gene Biotherapeutics Inc CRXM

Morningstar Rating
$0.00 0.00 (0.00%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

CRXM is trading at a 55% discount.
Price
$0.00
Fair Value
$4.23
Uncertainty
Extreme
1-Star Price
$6.76
5-Star Price
$1.87
Economic Moat
Ymbjxf
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CRXM is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.00
Day Range
$0.000.00
52-Week Range
$0.000.00
Bid/Ask
$0.00 / $0.05
Market Cap
$64.93
Volume/Avg
300 / 22,623

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Gene Biotherapeutics Inc is a clinical stage biotechnology company focused on pre-clinical, clinical, and commercialization of angiogenic gene therapy biotherapeutics for strategic niche markets primarily for the treatment of cardiovascular disease. The company's lead product candidate Generx is an angiogenic gene therapy product candidate designed for medical revascularization for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
3

Valuation

Metric
CRXM
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
CRXM
Quick Ratio
0.08
Current Ratio
0.08
Interest Coverage
−10.35
Quick Ratio
CRXM

Profitability

Metric
CRXM
Return on Assets (Normalized)
−216.41%
Return on Equity (Normalized)
Return on Invested Capital (Normalized)
Return on Assets
CRXM
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRHmsbqwshsKxjy$551.2 Bil
VRTX
Vertex Pharmaceuticals IncVjthwvvxyClhdww$101.9 Bil
REGN
Regeneron Pharmaceuticals IncDlymlwqnWcsgt$98.1 Bil
MRNA
Moderna IncMsvtqlwzsSmt$39.7 Bil
ARGX
argenx SE ADRBgsdcybzRkyw$22.1 Bil
BNTX
BioNTech SE ADRTmrdyctbFmzdg$20.8 Bil
ALNY
Alnylam Pharmaceuticals IncFrvlgptpYbydyl$18.6 Bil
BMRN
Biomarin Pharmaceutical IncYsfkvrtmWgmgbzd$17.2 Bil
RPRX
Royalty Pharma PLC Class AZppcrrczvjFyjvvh$12.3 Bil
INCY
Incyte CorpTsvsmhllMfkkqzl$11.9 Bil

Sponsor Center